“From the lab to a success story” / “Del laboratorio a un caso de éxito”. GlyCardial Diagnostics has been presented in one of the most famous Spanish newspapers (La Vanguardia).
Our vision is to improve the early diagnosis
of cardiac ischemic events to reduce
the impact of the disease on patients' life
Our vision is to improve the early diagnosis
of cardiac ischemic events to reduce
the impact of the disease on patients' life
of cardiac ischemic events to reduce
the impact of the disease on patients' life
GlyCardial Diagnostics is developing Apo J-Glyc as a novel biomarker for the diagnosis and prognosis of myocardial ischemia
Why?
Cardiovascular diseases (CVD) are the leading cause of death globally (30% total deaths). In 2016 17.5M people died from CVD and it is expected to reach up to 23.6M by 2030. Specifically, ischemic heart disease (IHD) is the leading cause of death from CVD accounting for 10 million deaths in 2016.
What?
Early detection of ischemia (lack of blood supply) is essential to prevent irreversible myocardial damage. Nowadays, there is an unmet medical need for early diagnosis of ischemia and the prediction of patients’ evolution after an ischemic event.
Apo J-Glyc is a novel biomarker for the diagnosis and prognosis of myocardial ischemia.
When?
3 years for the design, validation and CE marking of an Apo J-Glyc laboratory-based in vitro diagnostic test.
